Anatara Lifesciences trading on ASX
Anatara Lifesciences has listed on the ASX following its $7 million IPO. The shares started trading today under the ticker code ANR.
Anatara closed its oversubscribed IPO last week to help raise funds for the commercial development of non-antibiotic diarrhoea therapy Detach. The shares were priced at $0.50.
The company is focused on commercialising Detach in pigs first, and plans to use part of the proceeds to fund registration of the product for use in pigs in Australia, the EU and the US.
More long-term plans include expanding its use to other livestock and developing a version for human applications.
“This is an exciting day for Anatara as we take our first steps as a public company addressing an unmet need for effective non-antibiotic treatments and medicines,” Anatara Chairman Dr Mel Bridges said.
“We look forward to updating shareholders on our progress with Detach and seeing this important and innovative product enter the market.”
Anatara Lifesciences (ASX:ANR) shares were trading at 0.375 as of around 1.30 pm on Thursday.
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
